脊髄・胆管用筋萎縮治療の世界市場 2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Spinal and Bulbar Muscular Atrophy Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D0804-16696 • 出版社/出版日：GlobalInfoResearch / 2020年8月3日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、107ページ • 納品方法：Eメール • 産業分類：医薬品・治療

• 販売価格（消費税別）

Single User	￥487,200 (USD3,480)	▷ お問い合わせ
Multi User	￥730,800 (USD5,220)	▷ お問い合わせ
Corporate User	￥974,400 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、脊髄・胆管用筋萎縮治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。脊髄・胆管用筋萎縮治療の種類別市場規模（5α-レダクターゼ阻害剤、ゴナドトロピン放出ホルモンアゴニスト）、用途別市場規模（病院、整形外科クリニック、外来手術センター）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：AbbVie、Boehringer Ingelheim International、Johnson & Johnson、Pfizer、Sanofi、GlaxoSmithKline、Astellas Pharma、Century Pharmaceuticals ・地域別グローバル市場分析 2015年-2020年 ・脊髄・胆管用筋萎縮治療の北米市場（アメリカ、カナダ、メキシコ） ・脊髄・胆管用筋萎縮治療のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・脊髄・胆管用筋萎縮治療のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・脊髄・胆管用筋萎縮治療の南米市場（ブラジル、アルゼンチン） ・脊髄・胆管用筋萎縮治療の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：5α-レダクターゼ阻害剤、ゴナドトロピン放出ホルモンアゴニスト ・用途別分析：病院、整形外科クリニック、外来手術センター ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論

Market Overview
The Spinal and Bulbar Muscular Atrophy Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The global Spinal and Bulbar Muscular Atrophy Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx%% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

Market segmentation
Spinal and Bulbar Muscular Atrophy Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Spinal and Bulbar Muscular Atrophy Treatment market has been segmented into:
5α-Reductase Inhibitors
Gonadotropin-releasing Hormone Agonists

By Application, Spinal and Bulbar Muscular Atrophy Treatment has been segmented into:
Hospitals
Orthopedic Clinics
Ambulatory Surgical Centers

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Spinal and Bulbar Muscular Atrophy Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Spinal and Bulbar Muscular Atrophy Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Spinal and Bulbar Muscular Atrophy Treatment market.

The report offers in-depth assessment of the growth and other aspects of the Spinal and Bulbar Muscular Atrophy Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Spinal and Bulbar Muscular Atrophy Treatment Market Share Analysis
Spinal and Bulbar Muscular Atrophy Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Spinal and Bulbar Muscular Atrophy Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Spinal and Bulbar Muscular Atrophy Treatment sales, revenue and market share for each player covered in this report.

The major players covered in Spinal and Bulbar Muscular Atrophy Treatment are:
AbbVie
Boehringer Ingelheim International
Johnson & Johnson
Pfizer
Sanofi
GlaxoSmithKline
Astellas Pharma
Century Pharmaceuticals
Among other players domestic and global, Spinal and Bulbar Muscular Atrophy Treatment market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

レポート目次

---

1 Spinal and Bulbar Muscular Atrophy Treatment Market Overview
1.1 Product Overview and Scope of Spinal and Bulbar Muscular Atrophy Treatment
1.2 Classification of Spinal and Bulbar Muscular Atrophy Treatment by Type
1.2.1 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Type in 2019
1.2.3 5α-Reductase Inhibitors
1.2.4 Gonadotropin-releasing Hormone Agonists
1.3 Global Spinal and Bulbar Muscular Atrophy Treatment Market by Application
1.3.1 Overview: Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Orthopedic Clinics
1.3.4 Ambulatory Surgical Centers
1.4 Global Spinal and Bulbar Muscular Atrophy Treatment Market by Regions
1.4.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Spinal and Bulbar Muscular Atrophy Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Spinal and Bulbar Muscular Atrophy Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Spinal and Bulbar Muscular Atrophy Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Spinal and Bulbar Muscular Atrophy Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Spinal and Bulbar Muscular Atrophy Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Spinal and Bulbar Muscular Atrophy Treatment Status and Prospect (2015-2025)
2 Company Profiles
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business
2.1.3 AbbVie SWOT Analysis
2.1.4 AbbVie Product and Services
2.1.5 AbbVie Spinal and Bulbar Muscular Atrophy Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 Boehringer Ingelheim International
2.2.1 Boehringer Ingelheim International Details
2.2.2 Boehringer Ingelheim International Major Business
2.2.3 Boehringer Ingelheim International SWOT Analysis
2.2.4 Boehringer Ingelheim International Product and Services
2.2.5 Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 Johnson & Johnson
2.3.1 Johnson & Johnson Details
2.3.2 Johnson & Johnson Major Business
2.3.3 Johnson & Johnson SWOT Analysis
2.3.4 Johnson & Johnson Product and Services
2.3.5 Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer SWOT Analysis
2.4.4 Pfizer Product and Services
2.4.5 Pfizer Spinal and Bulbar Muscular Atrophy Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 Sanofi
2.5.1 Sanofi Details
2.5.2 Sanofi Major Business
2.5.3 Sanofi SWOT Analysis
2.5.4 Sanofi Product and Services
2.5.5 Sanofi Spinal and Bulbar Muscular Atrophy Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.6 GlaxoSmithKline
2.6.1 GlaxoSmithKline Details
2.6.2 GlaxoSmithKline Major Business
2.6.3 GlaxoSmithKline Product and Services
2.6.4 GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.7 Astellas Pharma
2.7.1 Astellas Pharma Details
2.7.2 Astellas Pharma Major Business
2.7.3 Astellas Pharma Product and Services
2.7.4 Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.8 Century Pharmaceuticals
2.8.1 Century Pharmaceuticals Details
2.8.2 Century Pharmaceuticals Major Business
2.8.3 Century Pharmaceuticals Product and Services
2.8.4 Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Spinal and Bulbar Muscular Atrophy Treatment Players Market Share
3.2.2 Top 10 Spinal and Bulbar Muscular Atrophy Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue and Market Share by Regions
4.2 North America Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
5 North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Countries
5.1 North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Countries (2015-2020)
5.2 USA Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
6 Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue by Countries
6.1 Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue by Countries (2015-2020)
6.2 Germany Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
6.4 France Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Revenue by Countries
7.1 Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Revenue by Countries (2015-2020)
7.2 China Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
7.5 India Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
8 South America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Countries
8.1 South America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Countries (2015-2020)
8.2 Brazil Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Spinal and Bulbar Muscular Atrophy Treatment by Countries
9.1 Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue and Market Share by Type (2015-2020)
10.2 Global Spinal and Bulbar Muscular Atrophy Treatment Market Forecast by Type (2019-2024)
10.3 5α-Reductase Inhibitors Revenue Growth Rate (2015-2025)
10.4 Gonadotropin-releasing Hormone Agonists Revenue Growth Rate (2015-2025)
11 Global Spinal and Bulbar Muscular Atrophy Treatment Market Segment by Application
11.1 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Application (2015-2020)
11.2 Spinal and Bulbar Muscular Atrophy Treatment Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Orthopedic Clinics Revenue Growth (2015-2020)
11.5 Ambulatory Surgical Centers Revenue Growth (2015-2020)
12 Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Forecast (2021-2025)
12.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Forecast (2021-2025)
12.2 Global Spinal and Bulbar Muscular Atrophy Treatment Market Forecast by Regions (2021-2025)
12.3 North America Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Forecast (2021-2025)
12.6 South America Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables
Table 1. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Spinal and Bulbar Muscular Atrophy Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Spinal and Bulbar Muscular Atrophy Treatment Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. AbbVie Corporate Information, Location and Competitors
Table 7. AbbVie Spinal and Bulbar Muscular Atrophy Treatment Major Business
Table 8. AbbVie Spinal and Bulbar Muscular Atrophy Treatment Total Revenue (USD Million) (2017-2018)
Table 9. AbbVie SWOT Analysis
Table 10. AbbVie Spinal and Bulbar Muscular Atrophy Treatment Product and Solutions
Table 11. AbbVie Spinal and Bulbar Muscular Atrophy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Boehringer Ingelheim International Corporate Information, Location and Competitors
Table 13. Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Major Business
Table 14. Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Total Revenue (USD Million) (2018-2019)
Table 15. Boehringer Ingelheim International SWOT Analysis
Table 16. Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Product and Solutions
Table 17. Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Johnson & Johnson Corporate Information, Location and Competitors
Table 19. Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Major Business
Table 20. Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Total Revenue (USD Million) (2017-2018)
Table 21. Johnson & Johnson SWOT Analysis
Table 22. Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Product and Solutions
Table 23. Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Pfizer Corporate Information, Location and Competitors
Table 25. Pfizer Spinal and Bulbar Muscular Atrophy Treatment Major Business
Table 26. Pfizer Spinal and Bulbar Muscular Atrophy Treatment Total Revenue (USD Million) (2017-2018)
Table 27. Pfizer SWOT Analysis
Table 28. Pfizer Spinal and Bulbar Muscular Atrophy Treatment Product and Solutions
Table 29. Pfizer Spinal and Bulbar Muscular Atrophy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Sanofi Corporate Information, Location and Competitors
Table 31. Sanofi Spinal and Bulbar Muscular Atrophy Treatment Major Business
Table 32. Sanofi Spinal and Bulbar Muscular Atrophy Treatment Total Revenue (USD Million) (2017-2018)
Table 33. Sanofi SWOT Analysis
Table 34. Sanofi Spinal and Bulbar Muscular Atrophy Treatment Product and Solutions
Table 35. Sanofi Spinal and Bulbar Muscular Atrophy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. GlaxoSmithKline Corporate Information, Location and Competitors
Table 37. GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Major Business
Table 38. GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Total Revenue (USD Million) (2017-2018)
Table 39. GlaxoSmithKline SWOT Analysis
Table 40. GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Product and Solutions
Table 41. GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. Astellas Pharma Corporate Information, Location and Competitors
Table 43. Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Major Business
Table 44. Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Total Revenue (USD Million) (2017-2018)
Table 45. Astellas Pharma SWOT Analysis
Table 46. Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Product and Solutions
Table 47. Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Century Pharmaceuticals Corporate Information, Location and Competitors
Table 49. Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Major Business
Table 50. Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Total Revenue (USD Million) (2017-2018)
Table 51. Century Pharmaceuticals SWOT Analysis
Table 52. Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Product and Solutions
Table 53. Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue (Million USD) by Players (2015-2020)
Table 55. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Players (2015-2020)
Table 56. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue (Million USD) by Regions (2015-2020)
Table 57. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Regions (2015-2020)
Table 58. North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Countries (2015-2020)
Table 59. North America Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Countries (2015-2020)
Table 60. Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue (Million USD) by Countries (2015-2020)
Table 61. Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Revenue (Million USD) by Countries (2015-2020)
Table 62. South America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Countries (2015-2020)
Table 63. South America Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Countries (2015-2020)
Table 64. Middle East and Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue (Million USD) by Countries (2015-2020)
Table 65. Middle East and Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Countries (2015-2020)
Table 66. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue (Million USD) by Type (2015-2020)
Table 67. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Type (2015-2020)
Table 68. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Forecast by Type (2021-2025)
Table 69. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2015-2020)
Table 70. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Application (2015-2020)
Table 71. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Forecast by Application (2021-2025)
Table 72. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Spinal and Bulbar Muscular Atrophy Treatment Picture
Figure 2. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Type in 2019
Figure 3. 5α-Reductase Inhibitors Picture
Figure 4. Gonadotropin-releasing Hormone Agonists Picture
Figure 5. Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Application in 2019
Figure 6. Hospitals Picture
Figure 7. Orthopedic Clinics Picture
Figure 8. Ambulatory Surgical Centers Picture
Figure 9. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue (USD Million) and Growth Rate (2015-2025)
Figure 10. North America Spinal and Bulbar Muscular Atrophy Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. South America Spinal and Bulbar Muscular Atrophy Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Middle East and Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Players in 2019
Figure 17. Global Top 5 Players Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share in 2019
Figure 18. Global Top 10 Players Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share in 2019
Figure 19. Key Players Market Share Trend
Figure 20. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 21. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Regions (2015-2020)
Figure 22. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Regions in 2018
Figure 23. North America Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 24. Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 25. Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 26. South America Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 27. Middle East and Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 28. North America Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Countries (2015-2020)
Figure 29. North America Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Countries in 2019
Figure 30. USA Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 31. Canada Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 32. Mexico Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 33. Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Countries (2015-2020)
Figure 34. Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Countries in 2019
Figure 35. Germany Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 36. UK Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 37. France Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 38. Russia Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 39. Italy Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 40. Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Countries (2015-2020)
Figure 41. Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Countries in 2019
Figure 42. China Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 43. Japan Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 44. Korea Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 45. India Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 46. Southeast Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 47. South America Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Countries (2015-2020)
Figure 48. South America Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Countries in 2019
Figure 49. Brazil Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 50. Argentina Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 51. Middle East and Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Countries (2015-2020)
Figure 52. Middle East and Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Countries in 2019
Figure 53. Saudi Arabia Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 54. UAE Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 55. Egypt Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 56. South Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue and Growth Rate (2015-2020)
Figure 57. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Type (2015-2020)
Figure 58. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Type in 2019
Figure 59. Global Spinal and Bulbar Muscular Atrophy Treatment Market Share Forecast by Type (2021-2025)
Figure 60. Global 5α-Reductase Inhibitors Revenue Growth Rate (2015-2020)
Figure 61. Global Gonadotropin-releasing Hormone Agonists Revenue Growth Rate (2015-2020)
Figure 62. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Application (2015-2020)
Figure 63. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Application in 2019
Figure 64. Global Spinal and Bulbar Muscular Atrophy Treatment Market Share Forecast by Application (2021-2025)
Figure 65. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 66. Global Orthopedic Clinics Revenue Growth Rate (2015-2020)
Figure 67. Global Ambulatory Surgical Centers Revenue Growth Rate (2015-2020)
Figure 68. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 69. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 70. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share Forecast by Regions (2021-2025)
Figure 71. North America Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Forecast (2021-2025)
Figure 72. Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Forecast (2021-2025)
Figure 73. Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Forecast (2021-2025)
Figure 74. South America Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Forecast (2021-2025)
Figure 75. Middle East and Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Forecast (2021-2025)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel

---